[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-427744-105":59,"doc-detail-427744-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","implementing-anti-amyloid-therapies-in-memory-clinics-a-qualitative-study-of-clinician-experiences","IMPLEMENTING ANTI-AMYLOID THERAPIES IN MEMORY CLINICS - A QUALITATIVE STUDY OF CLINICIAN EXPERIENCES","","Anti-amyloid therapies (AATs) have reshaped diagnosis and treatment for Alzheimer’s disease. An interdisciplinary team conducted a qualitative study of clinician experiences using semi-structured interviews with 27 prescribing clinicians across seven U.S. academic medical centers. The analysis identified themes covering how AATs alter diagnostic practice norms and disclosure, create opportunities and burdens through a shifting care paradigm, and expose variation in lecanemab treatment protocols and evolving eligibility criteria. Findings can guide workflow and decision-support interventions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/implementing-anti-amyloid-therapies-in-memory-clinics-a-qualitative-study-of-clinician-experiences/427744/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/implementing-anti-amyloid-therapies-in-memory-clinics-a-qualitative-study-of-clinician-experiences/427744.png","ImageObject",300,407,{"name":92,"@type":93},"Sophia Brooks","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-14","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study design and who participated?","Question",{"text":112,"@type":113},"The study used semi-structured interviews with 27 prescribing clinicians across seven U.S. academic medical centers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What key themes were identified in clinician experiences?",{"text":117,"@type":113},"Three themes were identified: changes to diagnostic practice norms, a paradigm shift with both hope and added burdens, and variation in lecanemab protocols and eligibility criteria over time.",{"name":119,"@type":110,"acceptedAnswer":120},"How might the findings be used in practice?",{"text":121,"@type":113},"Clinicians and institutions can consider structural workflow changes to support AAT implementation and inform development of AAT decision-support interventions.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},427744,1791063456,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":8,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":81},962084925636,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","742 Innovation in Aging, 2025, Vol. 9, No. S2  \nthematic content analysis. First, AATs affect practice norms for AD diagnosis. Clinicians feel added pressure for time-efficiency of the diagnostic process, sense expectations for more accurate diagnoses, and integrate AAT considerations into diagnostic disclosure and choice of tests. Even with increased time pressure, conversations about AATs are unfolding over multiple visits because of the time it takes for eligibility tests to return and to allow for shared decision-making. Second, the availability of AATs creates a paradigm shift with opportunities and challenges for clinicians. Clinicians describe feeling a sense of hope that isan ‘antidote’ to nihilism in dementia care. They also experience burdens from the increased workload and urgency of managing patients on infusion, inadequate institutional support, and reduced clinical time for patients not on AAT. Third, clinicians and institutions vary in lecanemab treatment protocols, including comfort with offering lecanemab to patients on concurrent anticoagulants or homozygous for ApoE4 . While institutional protocols initially adhered closely to published appropriate use criteria regarding patient eligibility, clinicians reported modifications of eligibility criteria over time. Clinicians and clinical leaders can use findings from this study to consider structural changes to accommodate new workflows related to AAT and to inform the development of AAT decision-support interventions.  \nAbstract citation ID: igaf122.2524  \nIMPLEMENTING ANTI-AMYLOID THERAPIES IN  \nMEMORY CLINICS: A QUALITATIVE STUDY OF  \nCLINICIAN EXPERIENCES  \nJoanna Paladino1, Anna Parks2, Daniel Dohan3, Seth Gale4, Liliana Ramirez Gomez1, Christine Ritchie1, Sachin Shah1, and Ayush Thacker1, 1. Massachusetts General Hospital, Boston, Massachusetts, United States, 2. University of Utah, Salt Lake City, Utah, United States, 3. University of California, San Francisco, San Francisco, California, United States, 4. Brigham and Women’s Hospital, Boston, Massachusetts, United States  \nAnti-amyloid therapies (AATs) have changed the diagnosis and treatment paradigm of Alzheimer’s disease (AD) . Our interdisciplinary team completed a qualitative study of clinicians’experience with AAT implementation. We conducted semi-structured interviews with 27 prescribing clinicians at seven  \nU.S. academic medical centers. We identified three themes using","cbCaiv1bBGX1MlQe","https://ap.wps.com/l/cbCaiv1bBGX1MlQe","pdf",670383,"English","# Clinician Experiences With AAT Implementation\n## Impact on Diagnostic Practices and Disclosure\n## Paradigm Shift: Opportunities and Burdens\n## Variation in Lecanemab Protocols and Eligibility Criteria","[{\"question\":\"What was the study design and who participated?\",\"answer\":\"The study used semi-structured interviews with 27 prescribing clinicians across seven U.S. academic medical centers.\"},{\"question\":\"What key themes were identified in clinician experiences?\",\"answer\":\"Three themes were identified: changes to diagnostic practice norms, a paradigm shift with both hope and added burdens, and variation in lecanemab protocols and eligibility criteria over time.\"},{\"question\":\"How might the findings be used in practice?\",\"answer\":\"Clinicians and institutions can consider structural workflow changes to support AAT implementation and inform development of AAT decision-support interventions.\"}]","IMPLEMENTING ANTI-AMYLOID THERAPIES IN MEMORY CLINICS - A QUALITATIVE STUDY OF CLINICIAN EXPERIENCES | PDF",1790644726]